Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.
Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, Banerjee S, Basu S. Suman S, et al. Among authors: banerjee s. Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1. Br J Radiol. 2019. PMID: 31600089 Free PMC article.
'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs.
Basu S, Abhyankar A, Kand P, Kumar R, Asopa R, Rajan MG, Nayak U, Shimpi H, Das T, Venkatesh M, Chakrabarty S, Banerjee S. Basu S, et al. Among authors: banerjee s. Nucl Med Commun. 2011 Jul;32(7):654-8. doi: 10.1097/MNM.0b013e328346350f. Nucl Med Commun. 2011. PMID: 21654355
The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results: will this dominate the therapeutic landscape and be an upfront consideration in metastatic castration-resistant prostate cancer in the coming years?
Basu S, Parghane RV, Joshi A, Prabhash K, Banerjee S. Basu S, et al. Among authors: banerjee s. Nucl Med Commun. 2018 Dec;39(12):1061-1063. doi: 10.1097/MNM.0000000000000932. Nucl Med Commun. 2018. PMID: 30339554 No abstract available.
Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods.
Adnan A, Deep K, Kameswaran M, Nikam D, Shanmukaih C, Dash A, Banerjee S, Basu S. Adnan A, et al. Among authors: banerjee s. J Nucl Med Technol. 2019 Dec;47(4):292-299. doi: 10.2967/jnmt.118.216754. Epub 2018 Nov 9. J Nucl Med Technol. 2019. PMID: 30413603 Free article. Clinical Trial.
9,328 results